Crescita Therapeutics Inc. (CTX.TO) Stock Analysis
A net-cash, near-zero-EV Canadian dermatology platform: operational turnaround and IP optionality priced like distress, with customer concentration as the sword over the thesis.
Overview
Crescita Therapeutics (TSX: CTX; OTC: CRRTF) is a Canadian micro-cap commercial dermatology company with an integrated model spanning in-house R&D, proprietary manufacturing, and a diversified portfolio of prescription and non-prescription skincare/aesthetics products. Headquartered in Laval, Québec (registry office Toronto), the company operates a 50,000 sq. ft., Health Canada-approved development/manufacturing facility that supports both proprietary brands and third-party contract manufacturing. Operations are reported across three segments: (1) **Commercial Skincare** (historically ~58–60% of revenue) selling physician-dispensed and premium dermocosmetic brands (Laboratoire Dr Renaud, Pro-Derm, Aquafolia, Alyria, Obagi) plus exclusive distribution of FILLMED injectables/NCTF and MicronJet devices; (2) **Manufacturing & Services (CMO)** (~35% of revenue) providing formulation, compounding, filling and packaging for external clients using a library of 250+ formulations; and (3) **Licensing & Royalties** (~6% but highest margin) monetizing IP—primarily Pliaglis, a phase-changing topical anesthetic (7% lidocaine/7% tetracaine) approved in 35+ countries and partnered globally. Geographically, revenue is concentrated in Canada (~60%), with the U.S. (~25%) and rest of world (~14–15%). The investment case is shaped by a 2025 pivot toward profitability and an unusually strong net-cash balance sheet versus a deeply depressed market valuation.